NMR-based metabolomics in real-time monitoring of treatment induced toxicity and cachexia in head and neck cancer: a method for early detection of high risk patients

Abstract

Introduction Nutritional treatment in head and neck squamous cell carcinoma cancer (HNSCC) patients undergoing radio-/chemo-radiotherapy (RT/CHRT) is complex and requires a multidisciplinary approach. In this study the real-time dynamic changes in serum metabolome during RT/CHRT in HNSCC patients were monitored using NMR-based metabolomics. Objectives The main goal was to find the metabolic markers that could help prevent of acute radiation sequelae (ARS) escalation. Methods 170 HNSCC patients were treated radically with RT/CHRT. Blood samples were collected weekly, starting from the day before the treatment and stopping within the week after the RT/CHRT completion, resulting in a total number of 1328 samples. 1 H NMR spectra were acquired on Bruker 400 MHz spectrometer at 310 K and analyzed using principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). Additional statistical analyses were performed on the quantified metabolites. Results PCA has detected a group of distinct outliers corresponding to ketone bodies (3HB, Ace, AceAce). These outliers were found to identify the individuals at high risk of weight loss, mainly by the 3HB changes, which was confirmed by the patients’ medical data. In the OPLS-DA models a transition from the lowest to the highest weight loss is seen, defining the metabolic time trajectories for the patients from the studied groups during RT/CHRT. 3HB is a relatively sensitive marker that allows earlier identification of the patients at higher risk of > 10% weight loss. Conclusion Our findings indicate that metabolic alterations, characteristic for malnutrition or cachexia, can be detected already at the beginning of the treatment, making it possible to monitor the patients with a higher risk of weight loss. Electronic supplementary material The online version of this article (10.1007/s11306-019-1576-4) contains supplementary material, which is available to authorized users.

Resolvin E1 in Follicular Fluid Acts as a Potential Biomarker and Improves Oocyte Developmental Competence by Optimizing Cumulus Cells

“…As a systematic analyzing tool for profiling metabolites, metabolomics was characterized for high resolution, sensitivity, and throughput in detecting a large population of molecules in various biological samples (8)(9)(10). In the last decade, the advance in metabolomic techniques allowed the identification of numerous individual chemicals in a small volume of biofluid.…”

Metabolic profiles of whole serum and serum-derived exosomes are different in head and neck cancer patients treated by radiotherapy

“…It was previously reported that altered metabolism of amino acid plays an important role in the response of HNC patients to RT [36]. For example, Boguszewicz and co-workers [4] demonstrated that decreased serum level of alanine, the main substrate for gluconeogenesis during fasting and cachexia, correlated with the acute radiation toxicity-associated weight loss in HNC patients undergoing RT. The whole-body response to irradiation frequently involves molecules associated with oxidative stress and in ammation [18].…”

“…The major bene t of RT is well established local control of the tumor. However, ionizing radiation induces damage to the adjacent healthy tissues, which is re ected at the systemic level in body uids [4][5][6][7]. Hence, detection in the patient's blood of molecular ngerprint of the body response to the treatment, which could potentially enable monitoring and prediction of radiation toxicity, is another important aspect of HNC diagnostics.…”

1H-NMR Based Serum Metabolomics Identifies Different Profile between Sarcopenia and Cancer Cachexia in Ageing Walker 256 Tumour-Bearing Rats

“…The elucidation of the molecular mechanisms of sarcopenia and cachexia is important to prevent the process of skeletal muscle atrophy and, consequently, improve the survival of cancer patients [4,5]. In this context, many studies have been interested in identifying circulating markers of muscle wasting process during cancer cachexia in clinical [6][7][8][9] and preclinical [10][11][12] models.…”

“…Metabolomics studies have revealed a distinct plasma, serum, and urine metabolic profile of cancer cachexia patients [6,7]. Additionally, Boguszewicz and colleagues [8] described serum metabolic alterations as a characteristic for malnutrition or cachexia that can already be detected at the beginning of the treatment of head and neck squamous cell carcinoma patients. Miller and colleagues [9] identified candidate markers of weight loss in patients with upper gastrointestinal cancer and the assessment of the therapeutic intervention.…”